EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Rhythm Pharmaceuticals's enterprise value is $2,131.03 Mil.
Rhythm Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-168.29 Mil. Therefore, Rhythm Pharmaceuticals's EV-to-EBITDA for today is -12.66.
The historical rank and industry rank for Rhythm Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
RYTM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.38 Med: -4.5 Max: 0.4
Current: -12.66
During the past 9 years, the highest EV-to-EBITDA of Rhythm Pharmaceuticals was 0.40. The lowest was -16.38. And the median was -4.50.
RYTM's EV-to-EBITDA is ranked worse than 100% of 473
companies
in the Biotechnology industry
Industry Median: 9.22
vs RYTM: -12.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-25), Rhythm Pharmaceuticals's stock price is $39.71.
Rhythm Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.200. Therefore, Rhythm Pharmaceuticals's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Rhythm Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Rhythm Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rhythm Pharmaceuticals's EV-to-EBITDA
For the Biotechnology subindustry, Rhythm Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Rhythm Pharmaceuticals's EV-to-EBITDA falls into.
Rhythm Pharmaceuticals EV-to-EBITDA Calculation
Rhythm Pharmaceuticals's EV-to-EBITDA for today is calculated as:
Rhythm Pharmaceuticals's current Enterprise Value is $2,131.03 Mil.
Rhythm Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-168.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Rhythm Pharmaceuticals's PE Ratio for today is calculated as:
Rhythm Pharmaceuticals's share price for today is $39.71.
Rhythm Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Rhythm Pharmaceuticals (Rhythm Pharmaceuticals) Business Description
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RYTM has been successfully added to your 